Implications of Homologous Recombination Deficiency for Neoadjuvant Platinum-Based Chemotherapy in Pancreatic Cancer: A Narrative Review.

Ann Surg Oncol · 2026 · PMC12982307 · PMID 41620555

Europe PMC DOI

hedged sentences

0.0700

closest p · 1.4× alpha

0.0800

boldest claim

The sentences

a positive trendP = 0.07so close (0.05 < p ≤ 0.1)

A similar retrospective analysis focusing on BRCA1/2 and PALB2 demonstrated a positive trend toward improved OS among HRD patients compared with HRP patients (hazard ratio [HR], 0.15; 95% confidence interval [CI], 0.02–1.23; P = 0.07). 56 Golan et al. 57 reported that among borderline resectable PDAC patients treated with neoadjuvant FOLFIRINOX, the pathologic complete response (pCR) rate was 44.4% for the BRCA2-mutated patients and 10% for the BRCA2 wild-type patients ( P = 0.009).

also in 11,005 other papers

did not reach statistical significanceP = 0.08so close (0.05 < p ≤ 0.1)

Although it did not reach statistical significance ( P = 0.08), this difference is clinically relevant for the HRD subgroup.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.